The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib

Crit Care. 2019 Mar 12;23(1):88. doi: 10.1186/s13054-019-2385-x.

Rémy Nyga¹, Laura Simon², Taieb Chouaki³, Caroline Delette², Youssef Bennis^{4

5}, Cedric Joseph^{6

7}, Jean-Pierre Marolleau^{2

8}, Michel Slama^{1

5}, Elie Zogheib^{1

5}, Julien Maizel^{9

10}

¹ Service de Médecine Intensive Réanimation, Rond point du Pr Cabrol, 80054, Amiens CEDEX 1, France.
² Department of Clinical Hematology and Cellular Therapy, Amiens University Hospital, Amiens, France.
³ Medical Parasitology and Mycology Department, Amiens University Hospital, Amiens, France.
⁴ Laboratory of Pharmacology and Toxicology, Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France.
⁵ MP3CV-EA 7517, Picardy Jules Verne University, Amiens, France.
⁶ Department of Infectious Diseases, Amiens University Hospital, Amiens, France.
⁷ AGIR: Microbiology Research Unit, EA4294, Equipe AGIR, Université de Picardie Jules Verne, Amiens, France.
⁸ EA 4666, Picardy Jules Verne University, Amiens, France.
⁹ Service de Médecine Intensive Réanimation, Rond point du Pr Cabrol, 80054, Amiens CEDEX 1, France. [email protected].
¹⁰ MP3CV-EA 7517, Picardy Jules Verne University, Amiens, France. [email protected].

No abstract available

Publication types